Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Expenses
Research and development	$ 4,167,287	$ 2,653,553
General and administrative	2,514,676	2,694,965
Total expenses	6,681,963	5,348,518
Loss from operations	(6,681,963)	(5,348,518)
Foreign exchange gains (losses)	5,493	(8,686)
Investment income	357,908	364,218
Non-cash interest expense for the sale of future royalties	(2,250,243)	(1,977,426)
Net loss	$ (8,568,805)	$ (6,970,412)
Net loss per share, basic	$ (1.13)	$ (1.31)
Net loss per share, diluted	$ (1.13)	$ (1.31)
Weighted average shares outstanding, basic	7,568,981	5,340,193
Weighted average shares outstanding, diluted	7,568,981	5,340,193